PT  - JOURNAL ARTICLE
AU  - Nash, Beatrice
AU  - Badea, Anthony
AU  - Reddy, Ankita
AU  - Bosch, Miguel
AU  - Salcedo, Nol
AU  - Gomez, Adam R.
AU  - Versiani, Alice
AU  - Silva, Gislaine Celestino Dutra
AU  - dos Santos, Thayza Maria Izabel Lopes
AU  - Milhim, Bruno H. G. A.
AU  - Moraes, Marilia M
AU  - Campos, Guilherme Rodrigues Fernandes
AU  - Quieroz, Flávia
AU  - Reis, Andreia Francesli Negri
AU  - Nogueira, Mauricio L.
AU  - Naumova, Elena N.
AU  - Bosch, Irene
AU  - Herrera, Bobby Brooke
TI  - Validating and modeling the impact of high-frequency rapid antigen screening on COVID-19 spread and outcomes
AID  - 10.1101/2020.09.01.20184713
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.09.01.20184713
4099  - http://medrxiv.org/content/early/2021/05/13/2020.09.01.20184713.short
4100  - http://medrxiv.org/content/early/2021/05/13/2020.09.01.20184713.full
AB  - High frequency screening of populations has been proposed as a strategy in facilitating control of the COVID-19 pandemic. We use computational modeling, coupled with clinical data from rapid antigen tests, to predict the impact of frequent viral antigen rapid testing on COVID-19 spread and outcomes. Using patient nasal or nasopharyngeal swab specimens, we demonstrate that the sensitivity/specificity of two rapid antigen tests compared to quantitative real-time polymerase chain reaction (qRT-PCR) are 82.0%/100% and 84.7%/85.7%, respectively; moreover, sensitivity correlates directly with viral load. Based on COVID-19 data from three regions in the United States and São José do Rio Preto, Brazil, we show that high frequency, strategic population-wide rapid testing, even at varied accuracy levels, diminishes COVID-19 infections, hospitalizations, and deaths at a fraction of the cost of nucleic acid detection via qRT-PCR. We propose large-scale antigen-based surveillance as a viable strategy to control SARS-CoV-2 spread and to enable societal re-opening.Competing Interest StatementBN, AB, AR, MB, NS, AG, and BBH are employed by E25Bio Inc. (www.e25bio.com), a company that develops diagnostics for epidemic viruses. BBH and IB are co-founders of E25Bio. AV, GCDS, TMILDS, BHGAM, MMM, GRFC, FQ, AFNR, MLN, and ENN do not have any competing interests.Funding StatementEN is funded by Tufts University DISC Seed Grant. MLN is supported by a FAPESP grant (#2020/04836-0) and is a CNPq Research Fellow. AFV is supported by a FAPESP Fellow grant (#18/17647-0). GRFC is supported by a FAPESP Fellow grant (#20/07419-0). BHGAM is supported by a FAPESP Scholarship (#19/06572-2). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PATH Samples: The primary study under which the samples and data were collected received ethical clearance from the PATH Research Ethics Committee, protocol number 00004244; all participants provided written informed consent for the use of the samples. The nasal swab specimens were de-identified, containing no demographic data, prior to analysis, and the experiments were performed in accordance with relevant guidelines and regulations. Brazil Samples: The primary study under which the samples and data were collected received ethical clearance from the Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP), protocol number 31588920.0.0000.5415; all participants provided written informed consent for the use of the samples. All excess samples and corresponding data were banked and de-identified prior to the analyses, and the experiments were performed in accordance with relevant guidelines and regulations. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials; any other data will be made available upon request. Our code can be found on github: https://github.com/badeaa3/COVID19_Rapid_Testing. https://github.com/badeaa3/COVID19_Rapid_Testing